Sepsivac
| Clinical data | |
|---|---|
| Other names | Mycobacterium w (heat killed) |
| Identifiers | |
| CAS Number | |
Sepsivac is a drug developed by
immunomodulatory, it modulates the immune system of the body and hence significantly reduces mortality rate in patients with gram negative sepsis. Sepsivac is a drug developed by CSIR and Cadila Pharmaceuticals under New Millennium Indian Technology Leadership Initiative (NMITLI) programme.[1] In many cases, Sepsivac has proven to provide effective care and relief to COVID patients.[2]
Sepsivac is approved by the
better source needed
]
Mechanism
In patients with sepsis, in response to an
Immunomodulator drugs such as Sepsivac regulate this host immune response.[4] Sepsivac is found to be safe in patients with no systematic side-effects. It can be used in combination with other treatments to manage a patient in critical care setting.[5]
Sepsivac and COVID
Scientists at CSIR found similarities between the clinical characteristics of patients with gram-negative sepsis and
AIIMS, Bhopal.[7]
References
- ^ a b Singh J (22 April 2020). "Indian Researchers Plan Clinical Trials of Sepsis Drug Against New Coronavirus". The Wire Science. Retrieved 28 April 2020.
- ^ Chakrabarti, Ganguly (29 April 2021). "Is there a way to tame the Covid virus?". @businessline. Retrieved 30 April 2021.
- ^ "Sepsivac – A First-In-The-World Innovation for Sepsis Management". Cadila Pharma.
- ISSN 0971-751X. Retrieved 28 April 2020.
- ^ Paliath S (22 April 2020). "Gram-negative sepsis drug to be trialled for treating critically-ill COVID-19 patients". www.indiaspend.com. Retrieved 28 April 2020.
- ^ "Sepsivac to be tested for COVID-19 treatment". The New Indian Express. 24 April 2020. Retrieved 28 April 2020.
- ^ Ray K (23 April 2020). "50-yr-old bacteria drug makes a comeback in fight against coronavirus". Deccan Herald. Retrieved 28 April 2020.
 | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |